Weekly Recap | Tonix Pharma -17.26%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.Tonix Pharma fell 17.26% this week to close at $6.04, underperforming the S&P 500 by about 15.31 percentage points. After touching $7.28 on Monday, the shares drifted lower through the week, hitting an intraday low of $6.01 on Wednesday before finishing at $6.04 on Friday. There was no major company catalyst during the week; trading was heavy early but settled into a lower-volume pullback.
The Week
Tonix Pharma fell 17.26% this week to close at $6.04, underperforming the S&P 500 by about 15.31 percentage points. After touching $7.28 on Monday, the shares drifted lower through the week, hitting an intraday low of $6.01 on Wednesday before finishing at $6.04 on Friday. There was no major company catalyst during the week; trading was heavy early but settled into a lower-volume pullback.
Analyst Ratings
Among the four brokers covering the stock, three rate it buy, one has no opinion, and none rate it hold or sell. The consensus rating is strong buy. The consensus target price is $44.5, or 636.75% above the current level. Targets range from $22 to $65, pointing to wide disagreement. The stock ranks 332nd out of 509 in the biotechnology industry.
The Week Ahead
On the macro calendar, the US releases the NAHB Housing Market Index on Monday (19 October), followed by housing starts and building permits on Tuesday, and EIA weekly crude and Cushing inventories on Wednesday. There are no material company filings this week and no earnings scheduled for the coming week.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.